Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab in Autoimmune Encephalitis
NCT03835728Phase 2Terminated
- Sponsor
- UT Southwestern Medical Center
- Start
- Jan 2019
- Primary completion
- Oct 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ocrelizumab in Autoimmune Encephalitis (AE), sponsored by UT Southwestern Medical Center. Started Jan 2019; status: terminated.
02
Drugs
ocrelizumab
03
Conditions
Autoimmune Encephalitis (AE)
Beyond the preview
Go deeper on NCT03835728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03835728.